DeepMed Research

9-aminocamptothecin

Generic Name: 9-aminocamptothecin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₇N_₃O_₄

CAS Number: 91421-43-1

Unique Ingredient Identifier: 5MB77ICE2Q

Background: Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.

Clinical Trials

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Leukemia, Myelocytic, Acute

First Posted Date: 2005-11-10

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 52

Registration Number: NCT00251368

Locations: 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-09-13

Last Posted Date: 2013-06-21

Lead Sponsor: Emory University

Registration Number: NCT00003551

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States

Aminocamptothecin in Treating Patients With T-cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-08-11

Last Posted Date: 2013-07-26

Lead Sponsor: Yale University

Target Recruit Count: 12

Registration Number: NCT00002635

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
New England Medical Center Hospital, Boston, Massachusetts, United States

Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-05-24

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00002671

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸
New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
🇺🇸
Overlook Hospital, Summit, New Jersey, United States

and more 3 locations

Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum

Phase 2

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-05-24

Last Posted Date: 2013-06-21

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003523

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 62 locations

Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-05-19

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT00003154

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: aminocamptothecin

First Posted Date: 2004-04-22

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00002745

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States
🇺🇸
Cooper Cancer Institute, Camden, New Jersey, United States
🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

and more 2 locations

Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: aminocamptothecin

First Posted Date: 2004-03-30

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT00003192

Locations: 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States

and more 4 locations

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2004-02-20

Last Posted Date: 2011-03-28

Lead Sponsor: NYU Langone Health

Target Recruit Count: 20

Registration Number: NCT00003548

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin

Phase 2

Completed

Conditions: Ovarian Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00001427

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy